Vanguard Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $268M | Buy |
10,674,865
+687,471
| +7% | +$16.1M | ﹤0.01% | 1390 |
|
|
2025
Q3 | $226M | Sell |
9,987,394
-167,357
| -2% | -$3.9M | ﹤0.01% | 1484 |
|
|
2025
Q2 | $176M | Buy |
10,154,751
+24,395
| +0.2% | +$452K | ﹤0.01% | 1568 |
|
|
2025
Q1 | $222M | Buy |
10,130,356
+84,331
| +0.8% | +$2.33M | ﹤0.01% | 1438 |
|
|
2024
Q4 | $321M | Buy |
10,046,025
+230,450
| +2% | +$6.93M | 0.01% | 1302 |
|
|
2024
Q3 | $283M | Buy |
9,815,575
+6,023
| +0.1% | +$223K | 0.01% | 1353 |
|
|
2024
Q2 | $376M | Buy |
9,809,552
+303,686
| +3% | +$13.8M | 0.01% | 1131 |
|
|
2024
Q1 | $559M | Sell |
9,505,866
-49,812
| -0.5% | -$3.18M | 0.01% | 944 |
|
|
2023
Q4 | $572M | Buy |
9,555,678
+85,701
| +0.9% | +$4.35M | 0.01% | 891 |
|
|
2023
Q3 | $360M | Buy |
9,469,977
+68,687
| +0.7% | +$3.02M | 0.01% | 1092 |
|
|
2023
Q2 | $856M | Sell |
9,401,290
-127,654
| -1% | -$11M | 0.02% | 662 |
|
|
2023
Q1 | $629M | Buy |
9,528,944
+316,453
| +3% | +$18.3M | 0.02% | 775 |
|
|
2022
Q4 | $476M | Buy |
9,212,491
+181,412
| +2% | +$9.62M | 0.01% | 899 |
|
|
2022
Q3 | $617M | Buy |
9,031,079
+304,334
| +3% | +$18M | 0.02% | 718 |
|
|
2022
Q2 | $395M | Buy |
8,726,745
+157,575
| +2% | +$7.18M | 0.01% | 1006 |
|
|
2022
Q1 | $435M | Buy |
8,569,170
+652,071
| +8% | +$28.8M | 0.01% | 1063 |
|
|
2021
Q4 | $374M | Buy |
7,917,099
+1,164,814
| +17% | +$45.9M | 0.01% | 1183 |
|
|
2021
Q3 | $223M | Buy |
6,752,285
+407,829
| +6% | +$22.9M | 0.01% | 1537 |
|
|
2021
Q2 | $401M | Buy |
6,344,456
+239,939
| +4% | +$12.4M | 0.01% | 1131 |
|
|
2021
Q1 | $262M | Buy |
6,104,517
+562,692
| +10% | +$26.6M | 0.01% | 1422 |
|
|
2020
Q4 | $317M | Buy |
5,541,825
+1,223,468
| +28% | +$51.8M | 0.01% | 1156 |
|
|
2020
Q3 | $130M | Sell |
4,318,357
-69,824
| -2% | -$2.09M | ﹤0.01% | 1548 |
|
|
2020
Q2 | $143M | Buy |
4,388,181
+1,354,710
| +45% | +$43.5M | 0.01% | 1484 |
|
|
2020
Q1 | $81.3M | Buy |
3,033,471
+619,157
| +26% | +$22M | ﹤0.01% | 1642 |
|
|
2019
Q4 | $73.9M | Buy |
2,414,314
+257,228
| +12% | +$7.12M | ﹤0.01% | 1912 |
|
|
2019
Q3 | $52M | Buy |
2,157,086
+106,248
| +5% | +$2.92M | ﹤0.01% | 2044 |
|
|
2019
Q2 | $52M | Buy |
2,050,838
+47,555
| +2% | +$968K | ﹤0.01% | 2079 |
|
|
2019
Q1 | $39.1M | Buy |
2,003,283
+563,245
| +39% | +$8.86M | ﹤0.01% | 2212 |
|
|
2018
Q4 | $19M | Buy |
1,440,038
+25,138
| +2% | +$386K | ﹤0.01% | 2465 |
|
|
2018
Q3 | $25.2M | Buy |
1,414,900
+72,610
| +5% | +$1.34M | ﹤0.01% | 2476 |
|
|
2018
Q2 | $29.5M | Buy |
1,342,290
+959,637
| +251% | +$22M | ﹤0.01% | 2388 |
|
|
2018
Q1 | $8.46M | Buy |
382,653
+108,579
| +40% | +$2.13M | ﹤0.01% | 2900 |
|
|
2017
Q4 | $5.95M | Buy |
+274,074
| New | +$4.03M | ﹤0.01% | 3059 |
|
Other funds holding APLS
ACA
DTC
RI
SCM
PCH
Vanguard Group's APLS Position: Q4 2025 in Review
Vanguard Group increased its Apellis Pharmaceuticals (APLS) stake by 6.9% in Q4 2025, buying an estimated $16.1M and bringing the position to 10,674,865 shares worth $268M. The position accounts for ﹤0.01% of the portfolio, ranked #1390.
Vanguard Group first reported a position in APLS in Q4 2017 and has held it in 33 quarters since. The position peaked at $856M in Q2 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.
- Vanguard Group held 10,674,865 shares of Apellis Pharmaceuticals worth $268M as of Q4 2025.
- Vanguard Group bought 687,471 Apellis Pharmaceuticals shares in Q4 2025, an estimated $16.1M.
- Apellis Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1390 holding.
- Vanguard Group first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 33 quarters since.
- Vanguard Group's Apellis Pharmaceuticals position peaked at $856M in Q2 2023.
- 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.